Quotient Limited (QTNT) is an established, commercial-stage transfusion diagnostics company with operations based in Switzerland, Scotland, and Pennsylvania. As of 2018, the company had 72 CE marked and 63 FDA licensed reagents, which generate a steady revenue stream for QTNT. However, its biggest potential lies in developing a unified platform called the MosaiQ, which combines 3 types of diagnostics - currently offered individually by competing companies - into one platform. This platform is in development in various stages, but once it is ready, it may have a disruptive effect on the transfusion diagnostics